VivaVision Biotech's FDA Meeting Outcome Paves Way for VVN461HD's Development in Uveitis Treatment VivaVision's innovative drug VVN461HD for uveitis treatment needs only one more clinical trial in the U.S. before its NDA submission, following FDA's positive feedback.

VivaVision Biotech's FDA Meeting Outcome Paves Way for VVN461HD's Development in Uveitis Treatment #China #VivaVision #Wenzhou #Uveitis #VVN461HD